Charles Bosworth

Charles Bosworth has served as the Chief Medical Officer at Azura Ophthalmics since July of 2017. He has a successful track record spanning 22 years across three major pharmaceutical companies with experience in devices and branded products for both the anterior and posterior segments of the eye and generic drug development. His expertise includes non-invasive medical diagnostics for developing, validating and implementing novel endpoints to support both global drug approvals and reimbursement dossiers. After obtaining his doctorate degree from the University of California at San Diego’s Shiley Eye Institute, he worked for Alcon Research Ltd. where he was responsible for the design and implementation of numerous programs developing novel treatments for ocular hypertension and glaucomatous optic neuropathy including Betaxolol, Travatan, Travance, Brimonidine tartrate, and numerous Phase 1 and 2a programs. Charles worked for Pfizer Inc. in San Diego, CA in 2004 as Ophthalmology Therapeutic Area Clinical Lead responsible for the technical review of all ongoing clinical development programs and the Ophthalmology Development Team Leader for glaucoma and dry eye. Some of the programs he directed included CP-690-550, a Janus Kinase Inhibitor for Dry Eye Disease, and PF-03187207, NO-Donating Latanoprost, for Primary Open Angle Glaucoma. He transitioned to Allergan, Plc. in Irvine, CA in 2010 where he served as a Global Team Leader for programs supporting the Restasis franchise, presbyopia, and novel Phase 1 and 2a programs across indications.